PT-141

Discover PT-141 Bremelanotide: A Breakthrough for Sexual Health

PT-141, also known as Bremelanotide, is a synthetic peptide derived from alpha-melanocyte-stimulating hormone. In particular, it serves as a potent agonist for melanocortin-4 (MC-4R) and melanocortin-1 (MC-1R) receptors. For example, clinical trials have extensively studied its role in treating hypoactive sexual desire disorder (HSDD) in both men and women. In addition, this peptide shows potential in managing acute hemorrhage. Approved by the FDA in 2019 for HSDD, Bremelanotide boosts sexual arousal and supports immune function. As a result, it stands out as a versatile melanocortin receptor agonist, offering benefits for sexual wellness and overall health.

PT-141 Bremelanotide Molecular Structure: Key Details for Researchers

Delve into the molecular structure of PT-141 Bremelanotide, a synthetic peptide crafted for therapeutic applications. Specifically, its chemical composition includes the following:

• Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
• Molecular Formula: C50H68N14O10
• Molecular Weight: 1025.2 g/mol
• PubChem CID: 9941379
• CAS Number: 189691-06-3

Derived from alpha-melanocyte-stimulating hormone, PT-141 targets melanocortin receptors (MC-4R and MC-1R) to enhance sexual arousal and immune support. Consequently, its unique structure makes it effective for addressing hypoactive sexual desire disorder (HSDD) and other conditions. Furthermore, researchers can explore its molecular design and applications in medical studies.

PT-141 Bremelanotide Research: Unlocking Its Potential

Benefits for Sexual Health

PT-141 Bremelanotide, a unique peptide, stimulates the central nervous system through melanocortin receptors (MC-4R and MC-1R). Unlike traditional treatments like PDE5 inhibitors (e.g., Viagra), it offers distinct advantages. For instance, research demonstrates its effectiveness in treating hypoactive sexual desire disorder (HSDD) in both men and women, increasing sexual arousal and satisfaction. Moreover, a pivotal study found PT-141 to be a strong alternative for men with erectile dysfunction (ED) unresponsive to sildenafil, often triggering erections within minutes.

Additional Medical Applications

In addition, PT-141 Bremelanotide shows promise in managing acute hemorrhage and supporting immune function. Due to its MC-1R activity, it may also address fungal infections and certain cancers. Furthermore, ongoing studies are exploring its potential in treating obesity and inflammation-related conditions, suggesting a broad therapeutic scope.

Antifungal and Anti-Inflammatory Effects

Thanks to its MC-1R activity, PT-141 exhibits antifungal and anti-inflammatory properties. As a result, it emerges as a promising candidate for combating infections and reducing morbidity in fungal conditions, according to recent studies.

Cancer Prevention Potential

Research indicates that PT-141’s MC-1R receptor activation may inhibit cancer cell growth. For example, it holds potential for treating carcinomas and squamous cell cancers, offering new avenues for oncology research.

Future Research Directions

Current studies are investigating PT-141 Bremelanotide’s broader applications. Specifically, its role in managing obesity, sexual dysfunction, hemorrhage, and inflammation is under scrutiny, paving the way for innovative treatments.

Side Effects and Tolerability

PT-141 Bremelanotide is well-tolerated in low doses, with minimal side effects in mice. However, in humans, subcutaneous administration may cause nausea. Nevertheless, its high bioavailability ensures it remains a viable therapeutic option.

PT-141 Bremelanotide References: Credible Sources

Given that credible research is vital, explore the scientific studies behind PT-141 Bremelanotide with these trusted references:

1. Sandrock A, Schmitz T, Schönberg K, et al. “Reproduction in corpora lutea number in obese melanocortin-4 receptor-deficient mice.” Reprod Biol Endocrinol, vol. 7, pp. 24, Mar 2009. [PubMed]
2. Rosen RC, Diamond LE, Earle DC, et al. “Evaluation of the safety, pharmacokinetics, and pharmacodynamic effects of subcutaneously administered PT-141 in healthy male subjects.” Int J Impot Res, vol. 16, pp. 155–142, Apr 2004. [PubMed]
3. Wessells H, Hruby VJ, Hackett G, et al. “Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 induces penile erection via brain and spinal melanocortin receptors.” Neuroscience, vol. 118, pp. 755–762, 2003. [PubMed]
4. Rostene JG, Plaus HK, et al. “Melanocortin agonist, melanotan II, enhances proceptive sexual behaviors in the female rat.” Pharmacol Biochem Behav, vol. 85, pp. 514–521, 2006. [PubMed]
5. Safarinejad M, Hosseini S. “Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo-controlled study.” Int J Impot Res, vol. 20, pp. 1066–1071, Mar 2008. [PubMed]
6. Clayton AH, et al. “Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.” Women’s Health (Lond), vol. 12, pp. 325–337, 2016. [PubMed]
7. Miller MK, Smith JR, Norman J, et al. “Expert opinion on existing and developing drugs to treat female sexual dysfunction.” Expert Opin Emerg Drugs, vol. 23, pp. 223–230, 2018. [PubMed]
8. “AMAG Pharmaceuticals and Palatin Technologies Enter Into Exclusive Licensing Agreement for North American Rights to Rekynda™ (bremelanotide), a Potential Treatment for a Common Female Sexual Disorder – AMAG Pharmaceuticals.” MarketWatch, 2017.
9. Ji H, et al. “The Synthetic Melanocortin (CKPV)2 Exerts Anti-Fungal and Anti-Inflammatory Effects against Candida albicans Vaginitis via Inducing Macrophage M2 Polarization.” PLoS ONE, vol. 8, Feb 2013. [PLoS ONE]
10. Maresca E, Flori M, and Picardo. “Skin phototype: a new perspective.” Pigment Cell Melanoma Res, vol. 28, pp. 378–389, Jul 2015. [PubMed]
11. Lefter R, et al. “Basal cell carcinoma, squamous cell carcinoma, and melanoma of the head and face.” Head Face Med, vol. 12, Feb 2016. [PubMed]
12. Clayton AH, et al. “Kingsberg et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.” Women’s Health (Lond), vol. 12, pp. 325–337; 2016; 1237/whl.2016-0018.
13. McMillan TR, et al. “Melanotan II, a melanocortin agonist, partially rescues the impaired thermogenic capacity of pituitary adenylate cyclase-activating polypeptide-deficient mice.” Exp Physiol, vol. 106, pp. 427–437, Feb 2021. [PubMed]
14. Spana C, et al. “Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials.” Diabetes Obes Metab, vol. 24, pp. 1084–1093, Jun 2022. [PubMed]